CISCER® at AOGIN Conference: DNA methylation for efficient detection and triage of high-grade cervical lesions
From July 11 to 13, 2024, the Asia-Oceania Genital Infection and Tumor Research Organization Conference (AOGIN) was successfully held in Seoul, South Korea. The theme of this conference is "Empowering Women to Fight Cervical Cancer Together". AOGIN is one of the most influential medical organizations in the Asia-Pacific region. It echoes EUROGIN, IPVS and IFCPC to cooperate in the fight against infectious diseases and cancer. It is committed to working with global institutions including various medical and health professionals to promote women's health and raise public awareness. The conference invited well-known organizations and associations in the Asia-Pacific region to discuss cooperation with experts, including the International Federation of Cervical Pathology and Colposcopy (IFCPC), the Chinese Society of Colposcopy and Cervical Pathology (CSCCP), the Thai Gynecological Cancer Society (TGCS), the Japanese Society of Gynecological Oncology (JSGO) and the International Papillomavirus Conference (IPVC).
This AOGIN conference mainly discussed topics such as cervical cancer epidemiology, prevention and treatment of lower genital tract lesions, control of HPV-related head and neck diseases, development of biomarkers for cervical lesions, application of HPV vaccines, HPV detection methods and triage of women with HPV-positive cervix, and treatment and management of cervical lesions. Experts from all over the world actively exchanged opinions and fully discussed new methods, technologies and new experiences in fighting cervical cancer. During the conference, AOGIN joined scholars from various countries to participate in the "For C" campaign to jointly look forward to a world without cervical cancer.
Medical Manager Liu Xingyu attended the 2024AOGIN Conference on behalf of CISPOLY and gave a research report entitled "Evaluating PAX1 and JAM3 Methylation Analysis as a Triage Testing for Women with ASC-US/AGC in Cervical Cancer Screening: A Comparative Analysis with HPV 16/18 Genotyping".
At the beginning of the report, Manager Liu summarized the arduous task of eliminating cervical cancer in China and the shortcomings of the non-invasive/minimally invasive cervical cancer screening and diagnosis methods used in early stage, including the low specificity of HPV detection and the low sensitivity of cytology examination. New technologies are needed to improve the efficiency and accuracy of early cervical cancer screening and diagnosis. At the same time, she proposed that DNA methylation technology can have the advantages of non-invasiveness, high detection accuracy and high detection efficiency compared with the current technology, and PAX1/JAM3 gene methylation detection technology can help the current environment.
Next, Manager Liu shared the results of the triage efficacy of PAX1/JAM3 gene methylation detection by Polyhe Biotechnology for patients with ASCUS/AGC in cytology. The study included a total of 1,336 subjects and explored the triage effect of PAX1/JAM3 gene methylation detection (Hegongkang CISCER®) on patients with both HPV testing and cytology results and ASCUS/AGC in cytology results.
The research results show that the methylation levels of PAX1 and JAM3 genes in "normal cervix/CIN1 lesions (CIN2-)" are significantly lower than "CIN2 or more severe lesions (CIN2+)". Most patients with CIN2 and CIN3 lesions will have at least one methylation marker (PAX1 or JAM3) positive, and all patients with cervical adenocarcinoma have positive PAX1 and JAM3 gene methylation tests. It indicates that Hegongkang CISCER® has high sensitivity in detecting high-grade cervical lesions and has high detection ability for cervical squamous cell carcinoma and adenocarcinoma.
Recommended by LinkedIn
In addition, for CIN2-lesions, compared with the 79.6% positive rate of high-risk HPV testing, the CISCER positive rate was only 17.9%. Compared with HPV testing, CISCER has balanced detection sensitivity and specificity. CISCER is indicated to significantly improve the efficiency and accuracy of cervical lesion screening and significantly reduce unnecessary colposcopy.
In the risk stratification of CIN3+ lesions, the risk prediction ability of CISCER for CIN3+ lesions (82.05%) was significantly higher than that of HPV 16/18 (33.33%) and high-risk HPV (20.43%).
Finally, Manager Liu concluded that the PAX1/JAM3 gene methylation (CISCER) marker has significant stratification ability for CIN2- and CIN2+ lesions; CICER shows a balanced and efficient ability to detect cervical lesions (sensitivity: 84.21% ; Specificity: 95.78%); Dual-gene methylation testing can improve the risk stratification ability for CIN3+ lesions; combined with HPV testing can eliminate possible missed diagnoses in current cervical cancer screening due to HPV negative or cytology above CIN3. DNA methylation testing has the potential to be a more accurate, more efficient, and more patient-acceptable screening method for cervical lesions, and it also has the potential to become an important part of future large-scale screening and health economic efficiency.
About CISPOLY
Beijing Origin Poly Bio-tec Co., Ltd. is a technology company driven by innovative technology and focusing on health. CISPOLY is a pioneer in the field of early diagnosis of gynecological tumors. With exclusive technology and patented markers as the core, it has developed early diagnosis products for gynecological tumors such as cervical cancer, endometrial cancer, and ovarian cancer, filling the gap in this field.
As women pay more and more attention to their own health, the women's health market will have great potential. In addition to the gynecological tumor early screening and early diagnosis product line, CISPOLY will also establish more women's health-related product pipelines in the future to create a leading technology innovation company in the women's health market.